Efficacy and safety of micafungin for febrile neutropenia in pediatric patients with hematological malignancies: A multicenter prospective study

Journal of Pediatric Hematology/Oncology

Volumn 35, Issue 7, 2013, Pages

  Kobayashi, Ryoji ^a   Suzuki, Nobuhiro ^b   Yoshida, Makoto ^c   Iizuka, Susumu ^d   Suzuki, Daisuke ^a   Sano, Hirozumi ^a   Kudoh, Tooru ^e  

^a SAPPORO HOKUYU HOSPITAL   (Japan)

^b SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c ASAHIKAWA MEDICAL COLLEGE   (Japan)

^d HOKKAIDO CANCER CENTER   (Japan)

^e HOKKAIDO MEDICAL CENTER   (Japan)

Author keywords

children; febrile neutropenia; hematological malignancy; micafungin

Indexed keywords

C REACTIVE PROTEIN; MICAFUNGIN;

ADOLESCENT; ARTICLE; BODY TEMPERATURE MEASUREMENT; CHILD; CLINICAL ARTICLE; COAGULASE NEGATIVE STAPHYLOCOCCUS; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; ENTEROCOCCUS; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFANT; LIVER DYSFUNCTION; MALE; MULTICENTER STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SCHOOL CHILD; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS CAPITIS; STAPHYLOCOCCUS EPIDERMIDIS; SYSTEMIC MYCOSIS; TREATMENT DURATION;

ADOLESCENT; ANTIFUNGAL AGENTS; CHILD; CHILD, PRESCHOOL; ECHINOCANDINS; FEMALE; FEVER; HEMATOLOGIC NEOPLASMS; HUMANS; INFANT; INFANT, NEWBORN; LIPOPEPTIDES; MALE; NEUTROPENIA; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84885174909     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e318299c6bd     Document Type: Article

References (28)

1. Kume H, Yamazaki T, Togano T, et al. Epidemiology of visceral mycoses in autopsy cases in Japan: comparison of the data from 1989, 1993, 1997, 2001, 2005 and 2007 in Annual of Pathological Autopsy Cases in Japan. Med Mycol J. 2011;52:117-127.
2. Corey L, Boeckh M. Persistent fever in patients with neutropenia. N Engl J Med. 2002;346:222-224.
3. Bakhshi S, Padmanjali KS, Arya LS. Infections in childhood acute lymphoblastic leukemia: an analysis of 222 febrile neutropenic episodes. Pediatr Hematol Oncol. 2008;25:385-392.
4. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34:730-751.
5. Jarvis B, Figgitt DP, Scott LJ. Micafungin. Drugs. 2004;64:969-982.
6. Kohno S, Masaoka T, Yamaguchi H, et al. A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan. Scand J Infect Dis. 2004;36:372-379.
7. Kuse ER, Chetchotisakd P, da Cunha CA, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet. 2007;369:1519-1527.
8. Pappas PG, Rotstein CM, Betts RF, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis. 2007;45:883-893.
9. Toubai T, Tanaka J, Ota S, et al. Efficacy and safety of micafungin in febrile neutropenic patients treated for hematological malignancies. Intern Med. 2007;46:3-9.
10. Tamura K, Urabe A, Yoshida M, et al. Efficacy and safety of micafungin, an echinocandin antifungal agent, on invasive fungal infections in patients with hematological disorders. Leuk Lymphoma. 2009;50:92-100.
11. Goto N, Hara T, Tsurumi H, et al. Efficacy and safety of micafungin for treating febrile neutropenia in hematological malignancies. Am J Hematol. 2010;85:872-876.
12. Park JS, Kim DH, Choi CW, et al. Efficacy and safety of micafungin as an empirical antifungal agent for febrile neutropenic patients with hematological diseases. Acta Haematol. 2010;124:92-97.
13. Kubiak DW, Bryar JM, McDonnell AM, et al. Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis. Clin Ther. 2010;32:637-648.
14. Seibel NL, Schwartz C, Arrieta A, et al. Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob Agents Chemother. 2005;49:3317-3324.
15. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med. 1999;340: 764-771.
16. Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med. 2004;351:1391-1402.
17. Maertens JA, Madero L, Reilly AF, et al. Caspofungin Pediatric Study Group. A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia. Pediatr Infect Dis J. 2010; 29:415-420.
18. Yamaguchi M, Kurokawa T, Ishiyama K, et al. Efficacy and safety of micafungin as an empirical therapy for invasive fungal infections in patients with hematologic disorders: a multicenter, prospective study. Ann Hematol. 2011;90: 1209-1217.
19. Burgess JL, Birchall R. Nephrotoxicity of amphotericin B, with emphasis on changes in tubular function. Am J Med. 1972;53:77-84.
20. Hitchcock CA, Pye GW, Troke PF, et al. Fluconazole resistance in Candida glabrata. Antimicrob Agents Chemother. 1993;37:1962-1965.
21. Niwa T, Shiraga T, Takagi A. Drug-drug interaction of antifungal drugs. Yakugaku Zasshi. 2005;125:795-805.
22. Pettengell K, Mynhardt J, Kluyts T, et al. FK463 South African Study Group. Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent. Aliment Pharmacol Ther. 2004;20:475-481.
23. van Burik JA, Ratanatharathorn V, Stepan DE, et al. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis. 2004;39:1407-1416.
24. Forrest GN, Rasetto F, Akpek G, et al. Safety and efficacy of micafungin in transplantation recipients. Transplantation. 2006;82:1549.
25. Heresi GP, Gerstmann DR, Reed MD, et al. The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants. Pediatr Infect Dis J. 2006;25: 1110-1115.
26. Denning DW,Marr KA, Lau WM, et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect. 2006;53:337-349.
27. Matsue K, Uryu H, Koseki M, et al. Breakthrough trichosporonosis in patients with hematologic malignancies receiving micafungin. Clin Infect Dis. 2006;42:753-757.
28. Akagi T, Yamaguti K, Kawamura T, et al. Breakthrough trichosporonosis in patients with acute myeloid leukemia receiving micafungin. Leuk Lymphoma. 2006;47:1182-1183.